Identification of Risk Factors Associated With Neoplastic Complications After Renal Transplantation in Nord-Pas de Calais , Normandy and Picardy Regions

Kidney transplantation is now the treatment of choice for end-stage renal disease (ESRD). Between 2800 and 3000 kidney transplants are performed each year in France and more than 33 000 patients are living with a functioning graft. Preventing allograft rejection requires the use of immunosuppressive therapy, the intensity decreases as the distance from the day of transplantation. Unfortunately, treatment favors certain complications, including infectious and neoplastic. These represent a major cause of mortality in these patients. If the frequency of skin cancer is greatly increased in this population, that of solid tumors remains a concern. Approximately 20% of patients develop cancer after 10 years of graft , half non- skin cancers, the main risk factor is immunosuppressive therapy . The aim of the study is to evaluate, in a large population of patients treated in 4 regions ( the Nord-Pas de Calais, the Upper and Lower Normandy and Picardy) risk factors (in particular the nature of the immunosuppressive treatment) of developing a neoplastic complication, skin cancers and solid tumors, after renal transplantation.

Sex

All

Minimum age

18 Years

Inclusion Criteria:

* All adult renal transplant patients in the 4 centers of interregion North - West
* Patients transplanted during the period from 1 January 2002 and 31 December 2011
* Patients recipients of first, second or third renal transplantation
* Patients transplant recipients from a living or deceased donor whatever the immunological risk
* Eligible patients will be included after being informed by their doctor and after accepting their data to be processed in the framework of this study
* Patient with a health insurance coverage

Exclusion Criteria:

* Patients transplanted as child
* Patients transplanted before 1 January 2002
* Patients followed in the interregion but transplanted in another center
* Patients recipients of a double transplant (two kidneys or kidney plus other organ)
* Patients that do not accept their medical data to be included in the database

• RESULTPommerolle P, Assem M, Uhl M, De Sousa P, Guerrot D, Hazzan M, Lobbedez T, Fourdinier O, Choukroun G. Renal Cell Carcinoma in Native Kidney After Kidney Transplantation: A Multicenter Case Control Study With a Focus on Screening Strategy. Transpl Int. 2025 Jun 16;38:14487. doi: 10.3389/ti.2025.14487. eCollection 2025. PMID 40590038